Ra Pharmaceuticals, Inc. (RARX) Touches $6.02 Low on Feb, 14; Moxian (MOXC) SI Increased By 24.32%

February 14, 2018 - By Nellie Frank

The stock of Ra Pharmaceuticals, Inc. (NASDAQ:RARX) reached all time low today, Feb, 14 and still has $5.60 target or 7.00% below today’s $6.02 share price. This indicates more downside for the $136.21M company. This technical setup was reported by Barchart.com. If the $5.60 PT is reached, the company will be worth $9.53M less. The stock decreased 7.95% or $0.52 during the last trading session, reaching $6.02. About 572,648 shares traded or 154.02% up from the average. Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Moxian Incorporated (NASDAQ:MOXC) had an increase of 24.32% in short interest. MOXC’s SI was 9,200 shares in February as released by FINRA. Its up 24.32% from 7,400 shares previously. With 8,400 avg volume, 1 days are for Moxian Incorporated (NASDAQ:MOXC)’s short sellers to cover MOXC’s short positions. The stock decreased 1.41% or $0.05 during the last trading session, reaching $3.5. About 600 shares traded. Moxian, Inc. (NASDAQ:MOXC) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Ra Pharmaceuticals, Inc. (NASDAQ:RARX) to report earnings on March, 5. They expect $-0.72 earnings per share, up 1.37% or $0.01 from last year’s $-0.73 per share. After $-0.68 actual earnings per share reported by Ra Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 5.88% negative EPS growth.

Among 3 analysts covering Ra Pharmaceuticals (NASDAQ:RARX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ra Pharmaceuticals had 5 analyst reports since August 24, 2017 according to SRatingsIntel. The stock of Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has “Buy” rating given on Thursday, August 24 by Jefferies. RBC Capital Markets maintained Ra Pharmaceuticals, Inc. (NASDAQ:RARX) rating on Tuesday, October 24. RBC Capital Markets has “Buy” rating and $21.0 target. The firm has “Outperform” rating by Credit Suisse given on Friday, November 10. The company was maintained on Tuesday, September 26 by Jefferies.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company has market cap of $136.21 million. The companyÂ’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. It currently has negative earnings. The Company’s lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria , as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP).

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>